Santen Oy

Industry · 8 registered clinical trials.

Status	Trial	Phase	Started
Completed	A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Gl Glaucoma, Ocular Hypertension	Phase 1	2014-06-01
Completed	Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015 Healthy Volunteers	Phase 1	2011-09-01
Completed	Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations Ocular Hypertension, Open-angle Glaucoma	Phase 3	2011-03-01
Completed	Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies Ocular Hypertension, Open-angle Glaucoma	Phase 3	2011-02-01
Completed	Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye D Ocular Hypertension, Open-Angle Glaucoma	Phase 3	2010-04-01
Completed	Interaction Study of Timolol Eye Drops and Paroxetine Capsules Healthy	Phase 1	2009-04-01
Completed	Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Taflupros Ocular Hypertension, Open-Angle Glaucoma	Phase 3	2008-01-01
Completed	Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulati Open-Angle Glaucoma, Ocular Hypertension	Phase 3	2005-09-01